Cue Biopharma (CUE) Enterprise Value (2017 - 2025)
Cue Biopharma (CUE) posted Enterprise Value of -$27.7 million for Q4 2025, down 113.9% sequentially from -$12.9 million in Q3 2025, and down 21.84% YoY from -$35.4 million in Q4 2024.
Cue Biopharma (CUE) Enterprise Value (2017 - 2025) Analysis & Trends
Cue Biopharma has reported Enterprise Value for 9 years, with the latest figure at -$27.7 million in Q4 2025.
- Quarterly Enterprise Value fell 21.84% year-over-year to -$27.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$27.7 million (down 21.84% YoY) and the FY2025 annual result came in at -$27.7 million, down 21.84% from the prior year.
- Enterprise Value retreated to -$27.7 million in Q4 2025 per CUE's latest filing, from -$12.9 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$12.9 million in Q3 2025 and troughed at -$76.3 million in Q4 2022.
- A 5-year average of -$48.2 million and a median of -$53.4 million in 2021 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2021 and 2025: Enterprise Value slumped 50.33% in 2021, then jumped 65.76% in 2025.
- Over 5 years, Enterprise Value stood at -$52.2 million in 2021, then tumbled by 46.12% to -$76.3 million in 2022, then jumped by 48.37% to -$39.4 million in 2023, then soared by 42.29% to -$22.7 million in 2024, then dropped by 21.84% to -$27.7 million in 2025.
- According to Business Quant data, Enterprise Value over the past three periods registered -$27.7 million, -$12.9 million, and -$28.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - | -17.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -27.69 Mn |
| Sep 30, 2025 | -12.95 Mn |
| Jun 30, 2025 | -27.96 Mn |
| Mar 31, 2025 | -14.05 Mn |
| Dec 31, 2024 | -22.73 Mn |
| Sep 30, 2024 | -32.42 Mn |
| Jun 30, 2024 | -30.03 Mn |
| Mar 31, 2024 | -41.03 Mn |
| Dec 31, 2023 | -39.39 Mn |
| Sep 30, 2023 | -54.69 Mn |
| Jun 30, 2023 | -57.89 Mn |
| Mar 31, 2023 | -66.20 Mn |
| Dec 31, 2022 | -76.29 Mn |
| Sep 30, 2022 | -59.18 Mn |
| Jun 30, 2022 | -66.13 Mn |
| Mar 31, 2022 | -67.93 Mn |
| Dec 31, 2021 | -52.21 Mn |
| Sep 30, 2021 | -67.63 Mn |
| Jun 30, 2021 | -73.92 Mn |
| Mar 31, 2021 | -73.26 Mn |